The Genomic Editing and Screening (GES) Core was established in 2012 with institutional funds. Initially, it provided cutting-edge RNA interference (RNAi) gene target knockdown technologies toward the discovery of novel cancer targets and elucidation of complex aberrant intracellular pathways. A central feature is the use of third generation Pol II-driven, enhanced Mir30-based shRNA for high functional protein knockdown efficiency at single-copy integration, using a diverse panel of packaged retro-and lentiviral plasmid backbones for effective delivery. Establishment of this platform subsequently allowed for the rollout in 2014 of CRISPR-Cas9 sgRNA single-gene and full-genome knockout technologies via pooled libraries. Realization that many cell types are easily transfectable and that discrete intracellular events such as activation, translocation, and cell- to-cell communication can be quantified using high-speed automated fluorescence microscopy, the Core initiated high content imaging and analysis (HCA) for arrayed siRNA experimentation. A natural extension of this 96/384 well plate format was then evolved into a workstation-based small molecule compound screening program, allowing investigators to effectively phenocopy newly-identified targets using chemical biology approaches. The most promising of these compounds are then matriculated into the Early Therapeutics Center (ETC) and Tri-Institutional Therapeutic Drug Initiative (TRI-I TDI). Overall, this multi-modal Core enables mechanism-based science through target identification and drug screening, offering custom reagents and services to a growing number of the Center?s members.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Owosho, Adepitan A; Zhang, Lei; Rosenblum, Marc K et al. (2018) High sensitivity of FISH analysis in detecting homozygous SMARCB1 deletions in poorly differentiated chordoma: a clinicopathologic and molecular study of nine cases. Genes Chromosomes Cancer 57:89-95
Konishi, Tsuyoshi; Shimada, Yoshifumi; Hsu, Meier et al. (2018) Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol 4:309-315
Escorcia, Freddy E; Steckler, Jeffrey M; Abdel-Atti, Dalya et al. (2018) Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model. Mol Imaging Biol 20:808-815
Yoon, Sam S (2018) The New American Joint Commission on Cancer Staging System for Soft Tissue Sarcomas: Splitting versus Lumping. Ann Surg Oncol 25:1101-1102
Turashvili, Gulisa; Morency, Elizabeth G; Kracun, Mihaela et al. (2018) Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. Int J Gynecol Pathol :
Horvat, Natally; Veeraraghavan, Harini; Khan, Monika et al. (2018) MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. Radiology 287:833-843
Romanoff, Anya; Zabor, Emily C; Stempel, Michelle et al. (2018) A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction. Ann Surg Oncol 25:2909-2916
Abla, Oussama; Jacobsen, Eric; Picarsic, Jennifer et al. (2018) Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131:2877-2890
Soumerai, Tara E; Donoghue, Mark T A; Bandlamudi, Chaitanya et al. (2018) Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res 24:5939-5947
Hsin, Jing-Ping; Lu, Yuheng; Loeb, Gabriel B et al. (2018) The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol 19:1137-1145

Showing the most recent 10 out of 8799 publications